Literature DB >> 2934111

Dopamine D-1 receptors in the parkinsonian brain.

J O Rinne, J K Rinne, K Laakso, P Lönnberg, U K Rinne.   

Abstract

Dopamine D-1 receptors were analyzed in the caudate nucleus, putamen, pallidum, substantia nigra and nucleus accumbens in 20 patients with Parkinson's disease and in 18 age-matched controls by the binding of [3H]flupenthixol. The binding was decreased in the substantia nigra in those parkinsonian patients who were not treated with levodopa. A significantly increased number of D-1 receptors was found in the putamen of patients with Parkinson's disease, especially in those who were treated with levodopa. The increased binding of [3H]flupenthixol was most prominent in those six parkinsonian patients who still had therapeutic response to levodopa. In addition, orofacial dyskinesias were seen in three of these patients. The results of this study indicate that there may be denervation supersensitivity of striatal neurons and also a loss of striatonigral neurons in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2934111     DOI: 10.1016/0006-8993(85)91441-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

Review 1.  Psychotic symptoms in Parkinson's disease. From description to etiology.

Authors:  Spiridon Papapetropoulos; D C Mash
Journal:  J Neurol       Date:  2005-07       Impact factor: 4.849

2.  Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization.

Authors:  M T Martin-Iverson; S M Stahl; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors.

Authors:  S Papapetropoulos; D C Mash
Journal:  J Neural Transm (Vienna)       Date:  2006-12-07       Impact factor: 3.575

4.  Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.

Authors:  H Shinotoh; O Inoue; K Hirayama; A Aotsuka; M Asahina; T Suhara; T Yamazaki; Y Tateno
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

Review 5.  Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson's disease.

Authors:  Abdelhamid Benazzouz; Omar Mamad; Pamphyle Abedi; Rabia Bouali-Benazzouz; Jonathan Chetrit
Journal:  Front Aging Neurosci       Date:  2014-05-13       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.